These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17051834)

  • 21. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
    Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
    Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
    Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
    Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
    Endo K; Konishi A; Sasaki H; Takada M; Tanaka H; Okumura M; Kawahara M; Sugiura H; Kuwabara Y; Fukai I; Matsumura A; Yano M; Kobayashi Y; Mizuno K; Haneda H; Suzuki E; Iuchi K; Fujii Y
    Lung Cancer; 2005 Dec; 50(3):375-84. PubMed ID: 16199108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.
    Lara-Guerra H; Waddell TK; Salvarrey MA; Joshua AM; Chung CT; Paul N; Boerner S; Sakurada A; Ludkovski O; Ma C; Squire J; Liu G; Shepherd FA; Tsao MS; Leighl NB
    J Clin Oncol; 2009 Dec; 27(36):6229-36. PubMed ID: 19884551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome.
    Ushiki A; Koizumi T; Kobayashi N; Kanda S; Yasuo M; Yamamoto H; Kubo K; Aoyagi D; Nakayama J
    Jpn J Clin Oncol; 2009 Apr; 39(4):267-70. PubMed ID: 19155283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
    Onitsuka T; Uramoto H; Nose N; Takenoyama M; Hanagiri T; Sugio K; Yasumoto K
    Lung Cancer; 2010 May; 68(2):198-203. PubMed ID: 19589612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
    Mitsudomi T; Kosaka T; Endoh H; Horio Y; Hida T; Mori S; Hatooka S; Shinoda M; Takahashi T; Yatabe Y
    J Clin Oncol; 2005 Apr; 23(11):2513-20. PubMed ID: 15738541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.
    Ikeda T; Nakamura Y; Yamaguchi H; Tomonaga N; Doi S; Nakatomi K; Iida T; Motoshima K; Mizoguchi K; Nagayasu T; Tsukamoto K; Kohno S
    Clin Lung Cancer; 2012 Sep; 13(5):369-74. PubMed ID: 22410386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.
    Tomizawa Y; Iijima H; Sunaga N; Sato K; Takise A; Otani Y; Tanaka S; Suga T; Saito R; Ishizuka T; Dobashi K; Minna JD; Nakajima T; Mori M
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6816-22. PubMed ID: 16203769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.
    Masago K; Fujita S; Togashi Y; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Sakamori Y; Mio T; Mishima M
    Oncol Rep; 2011 Oct; 26(4):795-803. PubMed ID: 21805046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
    Wu JY; Yu CJ; Shih JY; Yang CH; Yang PC
    Lung Cancer; 2010 Mar; 67(3):348-54. PubMed ID: 19473721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
    Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
    Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for EGFR mutations in lung cancer, a report from India.
    Sahoo R; Harini VV; Babu VC; Patil Okaly GV; Rao S; Nargund A; Venkataswamy E; Rao R; Kumar BS
    Lung Cancer; 2011 Sep; 73(3):316-9. PubMed ID: 21315473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.
    Pugh TJ; Bebb G; Barclay L; Sutcliffe M; Fee J; Salski C; O'Connor R; Ho C; Murray N; Melosky B; English J; Vielkind J; Horsman D; Laskin JJ; Marra MA
    BMC Cancer; 2007 Jul; 7():128. PubMed ID: 17626639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of epidermal growth factor receptor mutation in non-small-cell lung carcinoma using cytological and histological specimens.
    Xu H; Sun W; Zhang G; Cheng Y
    J BUON; 2015; 20(1):142-5. PubMed ID: 25778309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
    Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B
    Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
    Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
    Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer.
    Chen CM; Chang JW; Cheung YC; Lin G; Hsieh JJ; Hsu T; Huang SF
    Acta Radiol; 2008 Nov; 49(9):991-4. PubMed ID: 18651255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.